Loading
A Chinese-developed PD-1 blocker that became the first immunotherapy approved in the US for nasopharyngeal cancer.
Approved by the FDA 27 October 2023 with gemcitabine-cisplatin for first-line recurrent or metastatic NPC and as monotherapy after platinum (JUPITER-02, POLARIS-02); EU approval 2024 for NPC and oesophageal squamous cell carcinoma. Broadly approved in China across lung, oesophageal, urothelial, and other cancers. Junshi Biosciences; Coherus in the US.
Backbone ribbon from PDB 6JBT. RCSB PDB 6JBT. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Humanised IgG4 anti-PD-1 with a distinct epitope and slow off-rate. Connects to PD-1.
1.Binds PD-1 on T cells and blocks PD-L1/PD-L2 engagement
Source: www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf. Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. FDA-approved for nasopharyngeal carcinoma.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: toripalimab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2021-02-01 | Shanghai Junshi Biosciences to Coherus BioSciences Toripalimab (Loqtorzi), anti-PD-1 antibody; options on two further programmes | Licence | $150m | up to $1.11bn | source |
Compare all products across the US, EU, UK, Japan, China and Australia →
First FDA approval for nasopharyngeal carcinoma
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines |
| China | 2018 | Melanoma (first of many indications) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Toripalimab" OR ABSTRACT:"Toripalimab" OR TITLE:"Loqtorzi" OR ABSTRACT:"Loqtorzi") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Toripalimab, not a curated reading list.
Shares A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors, Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer, A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer, A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma.
Shares Li Zhang, Rui-Hua Xu, Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer, CSCO guidelines (China).
Shares A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors, A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors, A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours, A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours.
Shares Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer, Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer, DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer, Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma..
Shares Li Zhang, JUPITER-02, Rui-Hua Xu, CSCO guidelines (China).
Shares 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer, 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma, 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer, 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer.